ClinicalTrials.gg
Not yet recruitingNCT07875881Updated Oct 15, 2026

A Phase 3 Study of Deutenzalutamide in Patients With High-Risk BCR Prostate Cancer

A Phase 3 interventional study of Deutenzalutamide Soft Capsules + ADT and Placebo + ADT in High Risk Biochemical Recurrence (BCR) and Deutenzalutamide Soft Capsules, sponsored by Hinova Pharmaceuticals Inc.. Not yet recruiting at 3 sites in China. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Hinova Pharmaceuticals Inc. · Phase 3, Interventional, and Treatment

Updated Oct 15, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,044
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Study summary

This is a multicenter, randomized, double- blind, placebo-controlled Phase III trial to evaluate the efficacy and safety of Deutenzalutamide plus ADT versus placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer after definitive therapy.

02

Conditions studied

  • High Risk Biochemical Recurrence (BCR)
  • Deutenzalutamide Soft Capsules
03

In context

Lead sponsor

Hinova Pharmaceuticals Inc. is the lead sponsor of 8 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older men, be willing and able to provide .
  2. or cytologically confirmed adenocarcinoma of the prostate at initial , without neuroendocrine differentiation, signet cell, or small cell features.
  3. Prostate cancer initially treated by radical prostatectomy or radiotherapy (including brachytherapy) or both, with curative intent. Prostate cryoablation is not considered definitive therapy for this study, but its prior use is not exclusionary.
  4. BCR prostate cancer, PSA doubling time (PSADT)≤9 months as calculated by the sponsor.
  5. Screening PSA by the local laboratory as described in the protocol for patients who had radical prostatectomy (with or without radiotherapy) as primary treatment for prostate cancer and for patients who had radiotherapy only as primary treatment for prostate cancer .
  6. Serum testosterone by the local laboratory ≥150 ng/dL (5.2 nmol/L) at screening.
  7. (ECOG) performance status of 0 or 1 at screening.
  8. Estimated of ≥12 months.
  9. Able to swallow the study drug and comply with study requirements.
  10. Has adequate organ function.
  11. Must be willing to use reliable measures (eg, condom) and refrain from sperm donation throughout the study and through 3 months after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  1. Prior or present evidence of distant disease as assessed by computed tomography (CT) or magnetic resonance imaging (MRI) for soft tissue disease and whole-body radionuclide bone scan for bone disease. Patients with soft tissue pelvic disease may be eligible if the short axis of the largest lymph node is \<20 mm for lymph nodes below aortic bifurcation. If the screening bone scan shows a lesion suggestive of metastatic disease, the patient will be eligible only if a second imaging modality (CT, or MRI) does not show bone metastasis. If the imaging results are equivocal or consistent with metastasis by central radiology review, the patient is not eligible for enrollment.
  2. Prior hormonal therapy. /adjuvant therapy to treat prostate cancer ≤36 months in duration before randomization, or a single dose or a short course (≤6 months) of hormonal therapy given for rising PSA is allowed.
  3. Prior treatment with second-generation androgen receptor inhibitors (enzalutamide, darolutamide, apalutamide, rezvilutamide, deutenzalutamide, etc.), CYP17 inhibitors (abiraterone or ketoconazole, etc.), chemotherapy (docetaxel, etc.), immunotherapy (/PD-L1 inhibitors, etc.), or targeted therapy (PARP inhibitors, AKT inhibitors, etc.).
  4. Prior or planned bilateral orchiectomy.
  5. Major surgery within 4 weeks before randomization date.
  6. Treatment with 5-α reductase inhibitors (finasteride, dutasteride) within 4 weeks before randomization date.
  7. For patients who had a prior radical prostatectomy, a suitable candidate for salvage radiotherapy as determined by the investigator in consideration of appropriate guidelines.
  8. Participation in a clinical study of an agent that inhibits the androgen receptor or androgen synthesis (TAK-700, apalutamide, darolutamide, etc.); however, patients who received placebo are allowed.
  9. Use of any other investigational agent within 4 weeks before randomization date.
  10. Known or suspected or active .
  11. History of another invasive cancer within 3 years before screening, with the exception of fully treated cancers with a remote probability of recurrence. The medical monitor and investigator must agree that the possibility of recurrence is remote.
  12. cardiovascular disease including the following:

    1. Myocardial infarction within 6 months before screening;
    2. Unstable angina within 3 months before screening;
    3. class III or IV congestive heart failure or a history of New York Heart Association class III or IV congestive heart failure unless a screening echocardiogram or multigated acquisition scan performed within 3 months before the randomization date demonstrates a ≥45%;
    4. History of clinically significant ventricular arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes);
    5. History of Mobitz II second-degree or third-degree heart block without a permanent pacemaker in place;
    6. Screening (ECG): heart rate ≤50 beats per minute (bradycardia); >500 ms;
    7. Hypotension as indicated by a minimum of 2 consecutive blood pressure measurements showing systolic blood pressure \<90 mmHg at screening;
    8. Uncontrolled hypertension as indicated by a minimum of 2 consecutive blood pressure measurements showing systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg at screening.
  13. History of seizure or any condition that may predispose to seizure (eg, prior cortical stroke or significant brain trauma). History of loss of consciousness (unless of cardiac origin) or within 12 months before randomization.
  14. Gastrointestinal disorder affecting drug absorption or swallowing.
  15. History of bone marrow transplantation or organ transplantation requiring continued medical treatment.
  16. Known congenital or acquired immunodeficiency, active hepatitis, active tuberculosis, and other active infections.
  17. Known reaction to deutenzalutamide or any of capsule components (polyethylene glycol hydroxystearate, butylated hydroxyanisole, and butylated hydroxytoluene).
  18. to the use of androgen deprivation therapy (ADT).
  19. In the investigator's opinion, the participant is unsuitable for participation in this study (eg, not consistent with the most beneficial treatment for the participant, participant compliance).
  20. Ongoing drug or alcohol abuse as per investigator judgment.
  21. Any concurrent disease, infection, or comorbid condition that interferes with the ability of the patient to participate in the study, which places the patient at undue risk, or complicates the interpretation of data, in the opinion of the investigator or medical monitor.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,044 participants (estimated)

Study arms

  • Experimental
    Deutenzalutamide Soft Capsules+ ADT

    Deutenzalutamide Soft Capsules + ADT(Goserelin Acetate Sustained-release Implant)

    Drug: Deutenzalutamide Soft Capsules + ADT

  • Placebo comparator
    Placebo+ ADT

    Placebo + ADT(Goserelin Acetate Sustained-release Implant)

    Drug: Placebo + ADT

Interventions

  • DrugDeutenzalutamide Soft Capsules + ADT

    Deutenzalutamide Soft Capsules 80mg(Two capsules),QD, oral; ADT (Goserelin Acetate Sustained-release Implant) 10.8mg per dose, administered once every 12 weeks

  • DrugPlacebo + ADT

    Placebo Two capsules,QD, oral; ADT (Goserelin Acetate Sustained-release Implant) 10.8mg per dose, administered once every 12 weeks

06

What researchers measure

Primary outcomes

  1. MFS evaluated by BICR

    MFS was defined as the duration of time in months between randomization and the earliest objective evidence of radiographic progression by central imaging or death without radiographic progression, whichever occurred first.

    Time frame: Baseline, Week 25, 49 and every 24 weeks thereafter (± 5 days)

Secondary outcomes

  1. Time to Prostate-specific Antigen (PSA) Progression

    Time to PSA progression was defined as the time in months from randomization to the date of the first PSA value demonstrating progression, while participants were on study treatment, which was subsequently confirmed at least 3 weeks later.

    Time frame: From randomization until first PSA progression, assessed up to 36 months.

  2. Overall Survival

    Overall survival was defined as the time between randomization and death due to any cause.

    Time frame: From randomization until death due to any cause, assessed up to 60 months.

  3. Time to First Use of New Antineoplastic Therapy

    Time to first use of new antineoplastic therapy was defined as the time in months from randomization to first use of new antineoplastic therapy for prostate cancer.

    Time frame: From randomization until first use of new antineoplastic therapy, assessed up to 36 months.

  4. Time to distant metastasis

    The time to distant metastasis was defined as the time in months from randomization to the earliest objective evidence of distant soft tissue metastases or metastatic bone disease by blinded independent central review (BICR).

    Time frame: From randomization until radiographic progression or death without radiographic progression, whichever occurred first, assessed up to 36 months.

  5. Percentage of participants with undetectable PSA at Week 36 while on study treatment

    Undetectable PSA at 36 weeks was serum PSA levels \<0.2 ng/mL at Week 36. Percentage of participants with undetectable PSA at Week 36 while on study treatment was calculated as the number of participants with undetectable PSA at Week 36 divided by the number of participants with PSA values at Week 36 and multiplied by 100.

    Time frame: At Week 36.

  6. Percentage of participants who remain off treatment at 2 years after treatment suspension due to undetectable PSA at Week 36

    Percentage of participants who remain off treatment at 2 years after treatment suspension due to undetectable PSA at Week 36 was calculated as the number of participants who remained treatment-free 2 years after suspension of study treatment at Week 36 divided by the number of participants with treatment suspension and multiplied by 100.

    Time frame: From randomization until 2 years after Week 36, assessed up to 33 months.

  7. 7. Percentage of participants with sustained undetectable PSA at 2 years after treatment suspension due to undetectable PSA at Week 36

    Percentage of participants with sustained undetectable PSA at 2 years after treatment suspension due to undetectable PSA at Week 36 was calculated as the number of participants with undetectable PSA 2 years after suspension of treatment at Week 36 due to undetectable PSA divided by the number of participants with treatment suspension and multiplied by 100.

    Time frame: From randomization until 2 years after Week 36, assessed up to 33 months .

  8. Time to reinitiation of endocrine therapy after treatment suspension due to undetectable PSA at Week 36

    Time to reinitiation of endocrine therapy after treatment suspension due to undetectable PSA at Week 36 was defined as the time in months between the date of treatment suspension at Week 36 due to undetectable PSA and the date that hormonal therapy was restarted.

    Time frame: From treatment suspension at Week 36 until resumption of any hormonal therapy, assessed up to 36 months.

  9. Time to castration resistance

    Time to castration resistance was defined as the time in months from randomization to the first occurrence of radiographic disease progression by BICR, PSA progression or symptomatic skeletal event (SSE) whichever occurred first with castrate levels of testosterone (\<50 ng/dL).

    Time frame: From randomization to the first occurrence of radiographic disease progression, PSA progression or SSE, whichever occurred first with castrate levels of testosterone, assessed up to 36 months.

  10. Time to symptomatic progression

    Time to symptomatic progression was defined as the time in months from randomization to development of a skeletal-related event, worsening of disease-related symptoms requiring initiation of a new antineoplastic therapy, or development of adverse events (AEs) and clinically significant signs and/or symptoms due to loco-regional tumor progression requiring opiate use, surgical intervention or radiation therapy, whichever occurred first.

    Time frame: From randomization until the first development of events defined as symptomatic progression, assessed up to 36 months.

  11. Time to first symptomatic skeletal event

    Time to first symptomatic skeletal event was defined as the time in months from randomization to use of radiation therapy (external beam radiation therapy or radionuclides) or surgery to bone for prostate cancer, findings of clinically apparent pathologic bone fracture or of spinal cord compression, or new use of opiate and/or systemic antineoplastic therapy due to bone pain, whichever occurred first.

    Time frame: From randomization until the first development of events defined as SSE, assessed up to 36 months.

  12. Time to clinically relevant pain

    Time to clinically relevant pain was defined as the time from randomization to onset of pain progression, where clinically relevant pain progression was defined as a 2-point or greater increase from baseline in the BPI-SF question 3 score.

    Time frame: From randomization until a 2-point or greater increase from baseline in the BPI-SF question 3 score, assessed up to 36 months.

Other outcomes

  1. Progression-free survival on first subsequent therapy (PFS2)

    PFS2 was defined as the time from the date of randomization to the first occurrence of investigator-determined disease progression (PSA progression, progression on imaging, or clinical progression) or death due to any cause, whichever occurred first, while the patient was receiving first subsequent therapy for prostate cancer.

    Time frame: From randomization until PFS2, assessed up to 36 months.

07

Study locations

3 sites
08

References and documents

Individual participant data

Plan to share: No — All the unpublished information provided by the sponsor to the researchers and any data generated from this trial are confidential and are exclusive to the sponsor. The researchers agree to keep this information confidential and use it only to complete this study. Such information may not be used for any other purpose without the written consent of the sponsor. The trial results will be presented in the form of a clinical trial report (CSR), which includes the data from all participating units. Any data derived from the trial and involving copyright protection belong to the sponsor. The sponsor has the right to publish these materials and information.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Dec 2029, 38 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Oct 15, 2026
StartEst.
Oct 31, 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2031
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07875881
Lead sponsor
Hinova Pharmaceuticals Inc.
Responsible party
Sponsor
First posted
Oct 15, 2026
Start date
Oct 31, 2026 (estimated)
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Oct 15, 2026

Study contacts

Xinying Zhang
Contact
xyzhang@hinovapharma.com
86-18310792351

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion